Positive Phase III top-line results for Endo/BDSI pain drug; milestone triggered
This article was originally published in Scrip
Endo Pharmaceuticals and BioDelivery Sciences' (BDSI) have released positive top-line Phase III data for chronic pain drug BEMA buprenorphine, triggering a $10m milestone payment to the latter firm.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.